Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stake Reduced by Perceptive Advisors LLC

Perceptive Advisors LLC lowered its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by 0.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,250,000 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the period. Perceptive Advisors LLC’s holdings in Corbus Pharmaceuticals Holdings were worth $10,312,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in CRBP. Evanson Asset Management LLC raised its position in Corbus Pharmaceuticals Holdings by 1.8% in the first quarter. Evanson Asset Management LLC now owns 20,360 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 360 shares during the period. Bank of New York Mellon Corp raised its position in Corbus Pharmaceuticals Holdings by 7.7% in the first quarter. Bank of New York Mellon Corp now owns 21,102 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 1,511 shares during the period. Creative Planning raised its position in Corbus Pharmaceuticals Holdings by 2.4% in the first quarter. Creative Planning now owns 166,950 shares of the biopharmaceutical company’s stock valued at $1,377,000 after buying an additional 3,983 shares during the period. IPG Investment Advisors LLC bought a new position in Corbus Pharmaceuticals Holdings during the first quarter valued at approximately $109,000. Finally, Quantbot Technologies LP bought a new position in Corbus Pharmaceuticals Holdings during the first quarter valued at approximately $114,000. 28.26% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) traded down 0.86% during trading on Friday, hitting $5.75. The company’s stock had a trading volume of 692,516 shares. The firm’s 50 day moving average is $6.43 and its 200-day moving average is $7.59. The company’s market capitalization is $288.75 million. Corbus Pharmaceuticals Holdings, Inc. has a 1-year low of $2.62 and a 1-year high of $10.78.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). Corbus Pharmaceuticals Holdings had a negative return on equity of 117.78% and a negative net margin of 874.41%. The firm had revenue of $1.29 million during the quarter, compared to the consensus estimate of $2.50 million. Analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post ($0.77) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first reported by sleekmoney and is the property of of sleekmoney. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://sleekmoney.com/corbus-pharmaceuticals-holdings-inc-crbp-stake-reduced-by-perceptive-advisors-llc/1916199.html.

Several equities analysts recently commented on the company. Noble Financial reissued a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Sunday, March 12th. Cantor Fitzgerald reissued a “buy” rating and set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, April 5th. Finally, JMP Securities reissued an “outperform” rating and set a $27.00 price target (up from $20.00) on shares of Corbus Pharmaceuticals Holdings in a research report on Monday, April 3rd.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Want to see what other hedge funds are holding CRBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/corbus-pharmaceuticals-holdings-inc-crbp-stake-reduced-by-perceptive-advisors-llc/1916199.html

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *